MBGSBIO@EC2612A

Genscript Biotech Announces CARVYKTI® Sales of $555 Million for the Quarter

Huatai Securities Releases Report Analyzing JsR Biologics and Its Affiliate Legend Biotech's 2025 Performance

GenScript Biotech to Host Global Industry Forum

GENSCRIPT BIO released FY2025 Q1 earnings on August 17 (BJT), actual revenue HKD 2.018 B, actual EPS HKD -0.0458

Genscript Biotech Announces First Half of 2025 Unaudited Interim Results

GENSCRIPT BIO released FY2025 Q2 earnings on August 17 Pre-Market (BJT), actual revenue HKD 2.036 B, actual EPS HKD -0.0847

GENSCRIPT BIO released FY2025 Semi-Annual Earnings on August 17 Pre-Market (BJT), actual revenue HKD 4.054 B (forecast HKD 4.399 B), actual EPS HKD -0.1686 (forecast HKD 0.6279)

GENSCRIPT BIO to release FY2025 Semi-Annual earnings on August 16, 2025 (BJT), forecast revenue HKD 4.399 B, EPS HKD 0.6279

Genscript Biotech Expects Significant Increase in Pre-Tax Profit in H1 2025

Meng Jiange reduced his holdings of GenScript BioTech by 743,320 shares

Genscript Biotech receives EcoVadis Silver Rating

Genscript Biotech Exercises Share Options to Issue 1.2333 Million Shares

US House Panel Asks FBI for Information on China-linked Genetic Technologies

GS Biotech Affiliates Receive $214 Million in Payments

Chairman Meng Jiange of Junshi Biosciences Reduced Shares

GenScript Biotech Grants Restricted Shares to Employees

Genscript Biotech Exercises Options to Issue 1.6965M Shares

Savio Chow Reduced Shares of GenScript Biotech

Kinsey Biotech's Stock Up, Legend Biotech Announces Latest CARVYKTI® Treatment Results

Changes in Board Members of GS Bio

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

01548

LEGN

GENSCRIPT BIO (1548.HK) has recently seen a resurgence in its downward trend, with the daily MACD showing a death cross and a significant expansion of green bars, indicating a clear bearish trend in technical terms. The market shows a continuous decline in volume, with noticeable capital outflow and a strong wait-and-see sentiment among major players. Although there were signs of an oversold rebound yesterday, the trading volume failed to effectively increase, raising doubts about the sustainability of the rebound. The pharmaceutical sector has performed poorly overall recently, with investors' risk appetite declining, making it difficult for short-term thematic market momentum to emerge. 

On the fundamental side, GENSCRIPT BIO is at the forefront of innovative drug research and development, possessing medium to long-term growth potential. However, it is under pressure from industry regulations and price reductions due to centralized procurement, which has impacted profit growth expectations. Market funds tend to favor short-term risk aversion, and the sector as a whole lacks a systematic basis for upward movement. In the short term, without new clinical progress or significant cooperation news, it is challenging to reverse the weak market trend. 

Technically, the current stock price is near historical support levels, and close attention should be paid to the loss or gain of this support, as a breach could trigger accelerated declines. 

In terms of operational advice, short-term traders should closely monitor the flow of funds and trading activity in the market, and it is not advisable to blindly bottom-fish without accompanying volume. Conservative investors may wait for signs of stabilization in the sector and improvement in the company's fundamentals before entering the market. Pharmaceutical stocks may continue to be in a bottoming phase in the short term, with a focus on defensive holding and effective risk management. Future attention should be paid to the marginal changes in industry policies and their impact on the sector

Technical Forecast

GENSCRIPT BIO

Legend Biotech

Morning Trend | GENSCRIPT BIO's oversold rebound space is limited, can the pharmaceutical theme rise again?

Genscript Biotech has announced that its chairman, Jiange (Robin) Meng, will join the board of its associate company, Legend Biotech Corporation, effective January 20, 2026. This appointment aims to strengthen ties between the two companies and enhance strategic coordination. Investors are advised to be cautious, as the latest analyst rating for Genscript's stock is a Sell, with a price target of HK$13.00. Genscript Biotech is a Hong Kong-listed life sciences company with a strategic interest in Legend Biotech, which is listed on Nasdaq.

Tip Ranks

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech

01618

02539

09678

02591

00817

02570

02255

02469

01709

MCC(01618) fell 21.01%, with a trading turnover 907.7 Million HKD, and a year-to-date rose 19.1%. LEMO SERVICES(02539) fell 19.81%, with a trading turnover 43.4 Million HKD, and a year-to-date rose 70%. UNISOUND(09678) fell 19.42%, with a trading turnover 87.2 Million HKD, and a year-to-date rose 130.9%.

Top Gainers & Losers

LEMO SERVICES

UNISOUND

INNOGEN-B

CHINA JINMAO

REFIRE

HAICHANG HLDG

FENBI

DL HOLDINGS GP

Top 10 HK Stock Losers (12.9)

On November 20th, at the close, GENSCRIPT BIO (1548.HK) experienced price fluctuations throughout the day, maintaining a weak consolidation trend. After opening lower in the morning, both bulls and bears engaged in short-term tug-of-war. Although there was slight support, the overall trend was a continuous decline, with limited buying interest. The pharmaceutical and biotechnology sector showed weakened sentiment, with a scarcity of mainline hotspots in the sector. The news front lacked highlights, with no new drug applications, major agreements, orders, or new policy stimuli from the company. Market funds focused on high-growth technology and popular themes, while the pharmaceutical sector was in a cycle of institutional rotation and neglect. The MACD death cross structure remained unchanged, and the volume-price relationship was primarily characterized by shrinking volume and bottoming out. Intraday rebounds were mostly short-lived. The technical trend repeatedly tested important support zones, and the downward process lacked momentum, with no strong signals of stabilization seen in the bottom area. Right-side trading funds generally reduced risk exposure, and a wait-and-see sentiment dominated the market. If there are subsequent unusual movements in heavyweight pharmaceutical stocks or a significant increase in trading volume, the weak rebound window may be activated, but aggressive speculation is not recommended until the structure is repaired. Continuous attention should be paid to marginal events at the external and industry levels, such as the launch of important drugs in the sector, policy turning points, or favorable financing conditions. Once negative catalysts or policy strikes occur, the market's continued downside risk should be approached with high vigilance. The operational suggestion is to reduce risk positions and wait for right-side signals to appear

Morning Trend | GENSCRIPT BIO shows signs of bottom range fluctuation, with clear signals of main force wait-and-see

GENSCRIPT BIO announced that its joint venture Legend Biotech will present the latest data related to CARVYKTI® and other pipelines at the 67th Annual Meeting of the American Society of Hematology to be held in San Diego from December 6 to 9, 2025. The company submitted Form 6-K to the U.S. Securities and Exchange Commission on November 3, 2025

Zhitong

GENSCRIPT BIO: Legend will present the latest data at the American Society of Hematology Annual Meeting

According to the Zhitong Finance APP, GENSCRIPT BIO announced that, based on the collaboration and licensing agreement signed with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate net trade sales of approximately USD 524 million for the quarter ending September 30, 2025

GENSCRIPT BIO: CARVYKTI® generated net trade sales of approximately USD 524 million for the quarter ended September 30, 2025

GENSCRIPT BIO announced that it received a new payment of approximately RMB 480 million (about USD 67.5 million) from Pengbo according to the licensing agreement with LiXin Pharmaceutical Technology. This is the second sublicense revenue related to the anti-PD-1 single-domain antibody. By October 14, 2025, Pengbo has cumulatively received approximately RMB 2 billion (about USD 284 million). This amount will enhance Pengbo's cash reserves and support new molecular discovery and development

GENSCRIPT BIO: Prosperous received new payments based on the licensing agreement with Lixin Pharmaceutical Technology

XIACY

01810

600196

02196

00285

The Hong Kong stock market fell sharply in the morning session due to U.S. President Trump's threat to impose a 100% tariff on Chinese goods, with the Hang Seng Index dropping 916 points or 3.5% to 25,374 points. Mobile and pharmaceutical stocks were under pressure, with related stocks generally declining. Mobile component stocks such as GoerTek and BYD ELECTRONIC fell over 7%, while pharmaceutical stocks like FOSUN PHARMA and GENSCRIPT BIO dropped over 5%. The total market turnover was HKD 281.821 billion

AASTOCKS

Xiaomi Corporation

XIAOMI-W

FOSUN PHARMA

BYD ELECTRONIC

"Hong Kong Stocks" Hang Seng Index down 916 points in half a day, mobile and pharmaceutical stocks under pressure, Xiaomi down over 7%

According to the Zhitong Finance APP, GENSCRIPT BIO announced that on September 19, 2025, the company granted a total of 775,000 shares as rewards to its employees and one director, subject to acceptance and compliance with the terms and conditions of the 2019 Restricted Stock Unit Plan

GENSCRIPT BIO: According to the 2019 restricted stock unit plan, a total of 775,000 shares were granted as rewards

01873

300759

03759

603127

06127

002821

06821

300347

03347

The Hong Kong stock market's CRO sector plummeted across the board, with Tigermed down over 14%, VIVA BIOTECH down over 11%, Pharmaron down 10%, JOINN down over 9%, Asymchem, WuXi AppTec, and WuXi Biologics down over 7%, and GENSCRIPT BIO down nearly 6%

VIVA BIOTECH

Pharmaron

PHARMARON

JOINN

Asymchem

Tigermed

TIGERMED

According to the latest information from the Hong Kong Stock Exchange, on September 3rd, Chief Operating Officer Shao Weihui reduced her holdings in GENSCRIPT BIO by 115,538 shares, at a price of HKD 17.3544 per share, totaling approximately HKD 2.0051 million. After the reduction, the latest number of shares held is approximately 6.8385 million, with a latest holding ratio of 0.31%

Chief Operating Officer Shao Weihui reduced holdings in GENSCRIPT BIO by approximately 115,500 shares at a price of about HKD 17.35 per share

Goldman Sachs released a research report stating that GENSCRIPT BIO's performance in the first half of the 2025 fiscal year was mixed, with gross margins continuing to be under pressure. However, sales of business excluding Legend Biotech were generally in line with expectations. Management slightly raised the guidance for the life sciences business for 2025 from 10% to 15% to 13% to 15%, expecting this business to maintain steady growth. Goldman Sachs maintained a "Buy" rating on GENSCRIPT BIO, lowering the target price from HKD 27.34 to HKD 26.25, and revised the earnings per share forecasts for 2025 to 2027 from USD 0.07, USD 0.05, and USD 0.10 to a loss of USD 0.03, a loss of USD 0.01, and a profit of USD 0.03, to reflect the pressure on earnings

Goldman Sachs: Lowers GENSCRIPT BIO target price to HKD 26.25 and reduces earnings forecast

CICC maintains GENSCRIPT BIO's "Outperform Industry" rating and raises the target price by 22.2% to HKD 21.50, expecting to achieve milestones such as CD3 VHH licensing transactions by the end of 2025 to early 2026. The company's 1H25 performance met expectations, with revenue of USD 519 million, a year-on-year increase of 81.9%, and a gross margin of 61.8%. The life sciences business showed steady growth, with CDMO revenue reaching USD 250 million, a year-on-year increase of 511.1%

CICC: Maintains GENSCRIPT BIO "Outperform Industry" rating and raises target price to HKD 21.50

GENSCRIPT BIO released its interim results for the period ending June 30, 2025, reporting a loss attributable to the parent company of USD 25.462 million, a year-on-year decrease of 85.46%. Revenue from continuing operations was USD 519 million, an increase of 81.92% year-on-year. Revenue from life sciences services and products was approximately USD 248 million, an increase of 11.3% compared to the previous period. Adjusted gross profit was approximately USD 126 million, with a slight decrease in gross margin to 51.0%. Adjusted operating profit slightly decreased to USD 46.4 million, mainly due to increased investment in marketing transformation and R&D activities

GENSCRIPT BIO released its interim results, with a loss attributable to the parent company owners of USD 25.462 million, narrowing by 85.46% year-on-year

China Merchants Jinling International released a research report stating that it maintains a "Buy" rating and a target price of HKD 28.75 for GENSCRIPT BIO, optimistic about the valuation recovery driven by factors such as the new growth inflection point for Hongbo and Baijie, and Legend gradually reaching breakeven. The report indicates that the non-cell core business is expected to achieve profitability in the first half of 2025, with the company forecasting an adjusted pre-tax profit of USD 175 million to USD 205 million, compared to a loss of USD 128 million in the previous period. The firm expects the company's non-cell core business to achieve a slight profit in the first half of 2025, slightly exceeding its previous expectations. The firm noted that Carvykti sales in the second quarter of 2025 are expected to be approximately USD 439 million, a year-on-year increase of 136% and a quarter-on-quarter increase of 19%, slightly exceeding the firm's and market's previous expectations. With new production capacity coming online in Europe and the United States, the firm expects quarterly growth to further accelerate in the third quarter of 2025

CMB International: Optimistic about GENSCRIPT BIO's valuation recovery, target price HKD 28.75

MBGSBIO@EC2612A(26101.HK)

Morning Trend | GENSCRIPT BIO's oversold rebound space is limited, can the pharmaceutical theme rise again?

Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech

Top 10 HK Stock Losers (12.9)

Morning Trend | GENSCRIPT BIO shows signs of bottom range fluctuation, with clear signals of main force wait-and-see

GENSCRIPT BIO: Legend will present the latest data at the American Society of Hematology Annual Meeting